Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Van Gestel

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Technical Innovations & Patient Support in Radiation Oncology|May 17, 2021
Evaluation of the XVI dual registration tool for image-guided radiotherapy in prostate cancerFilipa Sousa, Younes Jourani, Robbe Van den Begin, et al.
Breast Cancer Research : BCR|November 24, 2022
Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registryCatherine Philippson, Samuel Larsen, Stéphane Simon, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 21, 2018
A feasibility study on adaptive <sup>18</sup>F-FDG-PET-guided radiotherapy for recurrent and second primary head and neck cancer in the previously irradiated territoryJulie Schatteman, Dirk Van Gestel, Dieter Berwouts, et al.
The Oncologist|February 13, 2015
Helical tomotherapy in head and neck cancer: a European single-center experienceDirk Van Gestel, Danielle Van den Weyngaert, Geert De Kerf, et al.
Frontiers in Immunology|March 27, 2026
Immuno-radiotherapy enhances tumor control and induces abscopal responses in a humanized mouse modelMorgane M Cogels, Matteo Serra, Hugues Duvillier, et al.
BMC Cancer|August 17, 2014
The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 proteinAn Wouters, Bea Pauwels, Natalie Burrows, et al.
Therapeutic Advances in Medical Oncology|October 25, 2021
Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinomaChristelle Bouchart, Jean-Luc Engelholm, Jean Closset, et al.
BMC Cancer|August 7, 2021
Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trialAlex De Caluwé, Laurence Buisseret, Philip Poortmans, et al.
JAMA Oncology|July 6, 2023
Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical TrialMathieu Spaas, Nora Sundahl, Vibeke Kruse, et al.
BMC Cancer|May 8, 2021
Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trialMathieu Spaas, Nora Sundahl, Eva Hulstaert, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Technical Innovations & Patient Support in Radiation Oncology|May 17, 2021
Evaluation of the XVI dual registration tool for image-guided radiotherapy in prostate cancerFilipa Sousa, Younes Jourani, Robbe Van den Begin, et al.
Breast Cancer Research : BCR|November 24, 2022
Intraoperative electron radiotherapy in early invasive ductal breast cancer: 6-year median follow-up results of a prospective monocentric registryCatherine Philippson, Samuel Larsen, Stéphane Simon, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|March 21, 2018
A feasibility study on adaptive <sup>18</sup>F-FDG-PET-guided radiotherapy for recurrent and second primary head and neck cancer in the previously irradiated territoryJulie Schatteman, Dirk Van Gestel, Dieter Berwouts, et al.
The Oncologist|February 13, 2015
Helical tomotherapy in head and neck cancer: a European single-center experienceDirk Van Gestel, Danielle Van den Weyngaert, Geert De Kerf, et al.
Frontiers in Immunology|March 27, 2026
Immuno-radiotherapy enhances tumor control and induces abscopal responses in a humanized mouse modelMorgane M Cogels, Matteo Serra, Hugues Duvillier, et al.
BMC Cancer|August 17, 2014
The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 proteinAn Wouters, Bea Pauwels, Natalie Burrows, et al.
Therapeutic Advances in Medical Oncology|October 25, 2021
Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinomaChristelle Bouchart, Jean-Luc Engelholm, Jean Closset, et al.
BMC Cancer|August 7, 2021
Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trialAlex De Caluwé, Laurence Buisseret, Philip Poortmans, et al.
JAMA Oncology|July 6, 2023
Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical TrialMathieu Spaas, Nora Sundahl, Vibeke Kruse, et al.
BMC Cancer|May 8, 2021
Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trialMathieu Spaas, Nora Sundahl, Eva Hulstaert, et al.
Pageof 8